Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Lopes

Showing results (131-140 of 177) with videos related to

Pageof 18
Sort By:
JCO Global Oncology|November 5, 2020
Recommendations from the ASCO Academic Global Oncology Task ForceJulie R Gralow, Fredrick Chite Asirwa, Ami Siddharth Bhatt, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
British Journal of Cancer|November 26, 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancerWungki Park, Laura Mezquita, Naoyuki Okabe, et al.
Clinical Genitourinary Cancer|December 27, 2014
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in SingaporeHui Shan Tan, Huihua Li, Yu Wen Hong, et al.
Clinical Lung Cancer|January 17, 2018
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With NivolumabWungki Park, Deukwoo Kwon, Diana Saravia, et al.
JCO Global Oncology|April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 ExperienceGilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
Expert Review of Anticancer Therapy|April 16, 2025
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, et al.
The Oncologist|February 25, 2025
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysisLuís F Leite da Silva, Erick F Saldanha, Júnior Samuel Alonso de Menezes, et al.
Cancers|April 27, 2024
The Genomic, Transcriptomic, and Immunologic Landscape of <i>HRAS</i> Mutations in Solid TumorsSamuel A Kareff, Asaad Trabolsi, Harris B Krause, et al.
JCO Global Oncology|August 7, 2020
Survey of the Impact of COVID-19 on Oncologists' Decision Making in CancerYüksel Ürün, Syed A Hussain, Ziad Bakouny, et al.
Pageof 18

Showing results (131-140 of 177) with videos related to

Sort By:
Pageof 18
JCO Global Oncology|November 5, 2020
Recommendations from the ASCO Academic Global Oncology Task ForceJulie R Gralow, Fredrick Chite Asirwa, Ami Siddharth Bhatt, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
British Journal of Cancer|November 26, 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancerWungki Park, Laura Mezquita, Naoyuki Okabe, et al.
Clinical Genitourinary Cancer|December 27, 2014
Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in SingaporeHui Shan Tan, Huihua Li, Yu Wen Hong, et al.
Clinical Lung Cancer|January 17, 2018
Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With NivolumabWungki Park, Deukwoo Kwon, Diana Saravia, et al.
JCO Global Oncology|April 6, 2021
OncoAlert Round Table Discussions: The Global COVID-19 ExperienceGilberto Morgan, Evandro de Azambuja, Kevin Punie, et al.
Expert Review of Anticancer Therapy|April 16, 2025
Prevalence and molecular correlates of acquired <i>EGFR</i> resistance mutations in non-small cell lung cancer (NSCLC)Luis E Raez, Yasmine Baca, Jennifer R Ribeiro, et al.
The Oncologist|February 25, 2025
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysisLuís F Leite da Silva, Erick F Saldanha, Júnior Samuel Alonso de Menezes, et al.
Cancers|April 27, 2024
The Genomic, Transcriptomic, and Immunologic Landscape of <i>HRAS</i> Mutations in Solid TumorsSamuel A Kareff, Asaad Trabolsi, Harris B Krause, et al.
JCO Global Oncology|August 7, 2020
Survey of the Impact of COVID-19 on Oncologists' Decision Making in CancerYüksel Ürün, Syed A Hussain, Ziad Bakouny, et al.
Pageof 18